Regulators hit Italian drugmaker with warning over manufacturing issues

Pills in blisters
Regulators hit ICI International Chemical Industry for failing to comply with good manufacturing practices at its Cellole, Italy plant. (Shutterstock)

Italian regulators slapped a warning letter on ICI International Chemical Industry for failing to comply with good manufacturing practices at its Cellole, Italy plant.

The Italian Medicines Agency found in a March 22 inspection of the facility that there were 19 major and nine other deficiencies related to “inadequate pharmaceutical quality systems that resulted in a number of issues.”

Those issues included poor deviations management and investigation, lack of documentation handling, lack of cleaning validation, lack of process validation, as well as a lack of analytical review and method validation and poor computer system validation.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

The agency called for the suspension of the company’s manufacturing authorization and withdrawal of its current valid GMP certificate.

The IMA cited the drug Spherotide (triptorelin), which is used to treat prostate cancer, in its letter posted on the EudraGDMP website.

According to a Bloomberg company profile, International Chemical was founded in 1989 and manufactures, fabricates or processes pharmaceuticals for human and veterinary use.

Suggested Articles

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.